Metastatic melanoma is the deadliest form of skin cancer, being responsible for 80% of skin cancer deaths. Small molecule colchicine-binding site inhibitors have previously demonstrated preclinical therapeutic efficacy in treating metastatic and paclitaxel-resistant melanoma. We report here on the design, synthesis, and biological evaluation of thirty-five novel triazoloquinoxaline-based compounds with promising therapeutic potential. The most potent analog, 9d, showed strong antiproliferative activity against a panel of melanoma cell lines (GI50 = 15.4 nM against A375) and binds to the colchicine site. Treatment with 9d in vitro arrests the cell cycle in the G2/M phase and induces apoptosis. In vivo, compound 9d (10 mg/kg) demonstrated a good safety profile, significantly inhibited tumor growth and proliferation, and induced leukocyte infiltration along with apoptosis and necroptosis in an immunocompetent B16-F10 syngeneic mouse model. Further evaluation of 9d has characterized its unique mechanism of inducing both apoptosis and necroptosis in treated melanoma cells.
Clark et al. (Tue,) studied this question.